SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that management will participate in the UBS Global Life Sciences Conference.
UBS Global Life Sciences Conference Grand Hyatt New York Thursday, September 27, 2007 9:00 a.m. ET
The presentation will be audio webcast live and available for replay from Dendreon’s website, http://www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
Dendreon Corporation
CONTACT: Greg Schiffman, Chief Financial Officer, +1-206-219-7179, orJennifer Cook Williams, Investor Relations, +1-206-829-1500, both ofDendreon Corporation
Web site: http://www.dendreon.com/
